Overcoming E3 Ligase-Mediated Resistance: Development of Novel Hydrophobic Tagging-Based Degraders Targeting ALK Protein.

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Shaowen Xie,Jingjie Zhu,Fangyi Zhan,Dazhi Feng,Chen He,Lihua Liu,Jia Xie,Jingyu Liu,Ming Zhong,Xingting Zhang,Jinyi Xu,Hong Yao,Shengtao Xu
{"title":"Overcoming E3 Ligase-Mediated Resistance: Development of Novel Hydrophobic Tagging-Based Degraders Targeting ALK Protein.","authors":"Shaowen Xie,Jingjie Zhu,Fangyi Zhan,Dazhi Feng,Chen He,Lihua Liu,Jia Xie,Jingyu Liu,Ming Zhong,Xingting Zhang,Jinyi Xu,Hong Yao,Shengtao Xu","doi":"10.1021/acs.jmedchem.5c00488","DOIUrl":null,"url":null,"abstract":"Traditional PROTACs, despite their groundbreaking role in targeted protein degradation (TPD), rely on E3 ubiquitin ligases and are vulnerable to resistance. In this study, we discovered norbornene- and bornane-based hydrophobic tags (HyTs) that efficiently degrade anaplastic lymphoma kinase (ALK). Notably, a novel hydrophobic tag, bornane was first identified. Both norbornene-based HyT J26 and bornane-based HyT J21 demonstrated significant degradation and antiproliferative activity in vitro. J26 achieves effective degradation of the EML4-ALK fusion protein in H3122 cells with CRBN expression knocked down via siRNA. In vivo, J26 significantly suppresses tumor growth with moderate oral bioavailability. Remarkably, J26 effectively targets ALK through the Hsp70 chaperone system and the ubiquitin-proteasome pathway, by passing the need for E3 ligase CRBN. This feature addresses a potential resistance mechanism arising from E3 ligase downregulation, thereby enhancing the potential of HyT technology in precision oncology.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"17 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00488","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Traditional PROTACs, despite their groundbreaking role in targeted protein degradation (TPD), rely on E3 ubiquitin ligases and are vulnerable to resistance. In this study, we discovered norbornene- and bornane-based hydrophobic tags (HyTs) that efficiently degrade anaplastic lymphoma kinase (ALK). Notably, a novel hydrophobic tag, bornane was first identified. Both norbornene-based HyT J26 and bornane-based HyT J21 demonstrated significant degradation and antiproliferative activity in vitro. J26 achieves effective degradation of the EML4-ALK fusion protein in H3122 cells with CRBN expression knocked down via siRNA. In vivo, J26 significantly suppresses tumor growth with moderate oral bioavailability. Remarkably, J26 effectively targets ALK through the Hsp70 chaperone system and the ubiquitin-proteasome pathway, by passing the need for E3 ligase CRBN. This feature addresses a potential resistance mechanism arising from E3 ligase downregulation, thereby enhancing the potential of HyT technology in precision oncology.
克服E3连接酶介导的抗性:开发新的基于疏水标记的ALK蛋白降解物。
传统的PROTACs,尽管在靶向蛋白降解(TPD)中具有开创性的作用,但依赖于E3泛素连接酶,容易受到耐药性的影响。在这项研究中,我们发现了降冰片烯和冰片烯基疏水标签(HyTs)可以有效地降解间变性淋巴瘤激酶(ALK)。值得注意的是,一个新的疏水标签,硼烷首次被发现。降冰片烯基HyT J26和冰片烯基HyT J21均表现出明显的体外降解和抗增殖活性。J26通过siRNA敲低CRBN表达,在H3122细胞中实现了EML4-ALK融合蛋白的有效降解。在体内,J26显著抑制肿瘤生长,口服生物利用度适中。值得注意的是,J26通过Hsp70伴侣系统和泛素-蛋白酶体途径,通过E3连接酶CRBN的需要,有效靶向ALK。这一特性解决了E3连接酶下调引起的潜在耐药机制,从而增强了HyT技术在精准肿瘤学中的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信